Cases & Deals

  • Home
  • Practices
  • Celgene successfully blocks Apotex's bid for inter partes review of REVLIMID® patent

Share

Celgene successfully blocks Apotex's bid for inter partes review of REVLIMID® patent

September 2018

Client(s) Celgene Corporation

Jones Day represented Celgene Corporation in successfully blocking institution of an inter partes review (IPR) petition filed by Apotex against U.S. Patent No. 8,741,929, which is listed in the Orange Book for Celgene's REVLIMID® brand drug. The '929 patent is directed to the use of REVLIMID® for the treatment of mantle cell lymphoma. Following Celgene's filing of its Patent Owner Preliminary Response, the Patent Trial and Appeal Board (PTAB) denied Apotex's petition in its entirety and declined to institute an IPR, finding that Apotex had failed to establish a reasonable likelihood that it would prevail in showing the unpatentability of any challenged claim of the '929 patent.

Apotex Inc., et al. v. Celgene Corp., IPR No. 2018-00685 (PTAB)

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.